309 related articles for article (PubMed ID: 37498506)
1. Flexible New Dosage Forms Containing Carvedilol for the Treatment of Patients with Cardiovascular Disorders: Development, Stability, Palatability, and Microbiological Studies.
Operto MA; Maggio R; Leonardi D; Vignaduzzo S
AAPS PharmSciTech; 2023 Jul; 24(6):159. PubMed ID: 37498506
[TBL] [Abstract][Full Text] [Related]
2. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Eckhardt M; Vermes A; Koch BC; Vulto AG; Hanff LM
Eur J Pharm Sci; 2017 Mar; 100():205-210. PubMed ID: 28126558
[TBL] [Abstract][Full Text] [Related]
3. Palatability and Stability Studies to Optimize a Carvedilol Oral Liquid Formulation for Pediatric Use.
Chiclana-Rodríguez B; Garcia-Montoya E; Romero-Obon M; Rouaz-El-Hajoui K; Nardi-Ricart A; Suñé-Pou M; Suñé-Negre JM; Pérez-Lozano P
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258041
[TBL] [Abstract][Full Text] [Related]
4. Development of carvedilol transdermal patches: evaluation of physicochemical, ex vivo and mechanical properties.
Gannu R; Vishnu YV; Kishan V; Rao YM
PDA J Pharm Sci Technol; 2008; 62(6):391-401. PubMed ID: 19634343
[TBL] [Abstract][Full Text] [Related]
5. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
6. Development of a Carvedilol Oral Liquid Formulation for Paediatric Use.
Chiclana-Rodríguez B; Garcia-Montoya E; Rouaz-El Hajoui K; Romero-Obon M; Nardi-Ricart A; Suñé-Pou M; Suñé-Negre JM; Pérez-Lozano P
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765252
[TBL] [Abstract][Full Text] [Related]
7. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
Chandrasekaran P; Kandasamy R
AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
[TBL] [Abstract][Full Text] [Related]
8. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
[TBL] [Abstract][Full Text] [Related]
9. Development of a stable oral liquid dosage form of spironolactone.
Pramar Y; Das Gupta V; Bethea C
J Clin Pharm Ther; 1992 Aug; 17(4):245-8. PubMed ID: 1429919
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture.
Joshi HN; Tejwani RW; Davidovich M; Sahasrabudhe VP; Jemal M; Bathala MS; Varia SA; Serajuddin AT
Int J Pharm; 2004 Jan; 269(1):251-8. PubMed ID: 14698596
[TBL] [Abstract][Full Text] [Related]
11. Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation.
Zhang Q; Huang B; Xue H; Lin Z; Zhao J; Cai Z
Mol Pharm; 2021 Jun; 18(6):2298-2310. PubMed ID: 34032449
[TBL] [Abstract][Full Text] [Related]
12. Design of ultra-fine carvedilol nanococrystals: Development of a safe and stable injectable formulation.
Mohammady M; Hadidi M; Iman Ghetmiri S; Yousefi G
Eur J Pharm Biopharm; 2021 Nov; 168():139-151. PubMed ID: 34481906
[TBL] [Abstract][Full Text] [Related]
13. Formulation and evaluation of carvedilol melt-in-mouth tablet using mucoadhesive polymer and PEG-6-stearate as hydrophilic waxy binder.
Dangi AA; Zalodiya PB
Int J Pharm Investig; 2012 Oct; 2(4):183-8. PubMed ID: 23580934
[TBL] [Abstract][Full Text] [Related]
14. Effect of casting solvent, film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an
El-Bary AA; Al Sharabi I; Haza'a BS
Drug Dev Ind Pharm; 2019 Nov; 45(11):1751-1769. PubMed ID: 31416366
[TBL] [Abstract][Full Text] [Related]
15. Development of clinical dosage forms for a poorly water-soluble drug II: formulation and characterization of a novel solid microemulsion preconcentrate system for oral delivery of a poorly water-soluble drug.
Li P; Hynes SR; Haefele TF; Pudipeddi M; Royce AE; Serajuddin AT
J Pharm Sci; 2009 May; 98(5):1750-64. PubMed ID: 18781639
[TBL] [Abstract][Full Text] [Related]
16. Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.
Trastullo R; Dolci LS; Passerini N; Albertini B
Int J Pharm; 2015 Nov; 495(1):536-550. PubMed ID: 26386139
[TBL] [Abstract][Full Text] [Related]
17. Development and pharmaceutical evaluation of oral fast dissolving thin film of escitalopram: A patient friendly dosage form.
Mushtaque M; Muhammad IN; Fareed Hassan SM; Ali A; Masood R
Pak J Pharm Sci; 2020 Jan; 33(1):183-189. PubMed ID: 32122847
[TBL] [Abstract][Full Text] [Related]
18. [Development of semisolid dosage form of clonazepam for oral cavity administration].
Sakata O; Onishi H; Machida Y
Yakugaku Zasshi; 2010 Jan; 130(1):119-25. PubMed ID: 20046075
[TBL] [Abstract][Full Text] [Related]
19. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
Bozdağ S; Gümüş K; Gümüş O; Unlü N
Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and microbiological stability of two news oral liquid formulations of clonidine hydrochloride for pediatric patients.
Merino-Bohórquez V; Delgado-Valverde M; García-Palomo M; Dávila-Pousa MC; Cañete C; Villaronga M; Rodriguez-Marrodán B; López-Rojas R; Cameán-Fernández M;
Pharm Dev Technol; 2019 Apr; 24(4):465-478. PubMed ID: 30124097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
